Shilpa Medicare Ltd receives Europe approval for Amifampridine Tablets, 10 mg

Shilpa Medicare Limited, headquartered at Raichur, Karnataka, India, has received Marketing Authorization from Germany, EU for Amifampridine Tablets, 10 mg under the National Procedure.

Amifampridine is used as a drug, predominantly in the treatment of a number of rare muscle diseases. Specifically, Amifampridine is used to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease.

This product has sales of about 20 M USD in Europe. As on date, there is one other approved generic in the market.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 329.70 as compared to the previous close of Rs. 329.35. The total number of shares traded during the day was 13640 in over 940 trades.

The stock hit an intraday high of Rs. 330.70 and intraday low of 319.90. The net turnover during the day was Rs. 4459939.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 MarketingAuthorization Germany EU AmifampridineTablets